Porphobilinogen deaminase (PBGD) is a rate-limiting enzyme of the heme biosynthesis pathway, whose level is elevated in various human tumors. PBGD was observed in both nuclear and cytoplasmic fractions of C6 glioma cells by immunostaining. During mitosis, chromatids were intensely stained for PBGD in comparison to the interphase chromatin. Using the yeast two-hybrid system, we identified RanBPM, the nuclear Ran-binding protein, as an interacting partner of PBGD. During butyrateinduced differentiation of C6, both nuclear and cytoplasmic PBGD levels declined as did Ran protein and its nucleotide exchange factor RCC1. N,N 0 -hexamethylene bis-acetamide-dependent differentiation resulted in an increase of the cytoplasmic PBGD, whereas nuclear PBGD, Ran protein and RCC1 remained unchanged. mRNA levels of PBGD remained unchanged during stimulation with both butyrate and N,N 0 -hexamethylene bis-acetamide. The enzymatic activity of PBGD and protoporphyrin IX synthesis in C6 cells were dependent on the differentiation induction agent. We conclude that PBGD possibly has a nuclear role in addition to its cytosolic enzymatic activity required for heme synthesis, which is related to cell transformation and differentiation.
Introduction
Various human tumors and leukemic cells accumulate protoporphyrin IX (PpIX) after exposure to the natural precursor 5-aminolevulinic acid (5-ALA) through the biosynthetic pathway of PpIX (Malik and Lugaci, 1987; Kennedy et al., 1990; Peng et al., 1997a, b) . This phenomenon is exploited for photodynamic therapy (PDT) of cancer due to the fact that PpIX absorbs light and subsequently produces singlet oxygen, which selectively eradicates the tumor. The porphyrin biosynthesis pathway consists of several enzymatic steps. glycine þ succ.CoA-5-ALA-porphobilinogen (PBG)-uroporphyrinogencoproporphyrinogen-protoporphyrin þ Fe 2 þ -heme. A rate-limiting determinant of this pathway is the third enzyme, porphobilinogen deaminase (PBGD), and is therefore considered to be the key enzyme in photodynamic therapy (Gibson et al., 1998 ). An increased growth rate in both nonmalignant and malignant cell lines was strongly correlated with an increased activity of PBGD (Schoenfeld et al., 1988) . PpIX biosynthesis and accumulation in a variety of malignant tissues following 5-ALA administration has been clinically exploited for photodynamic therapy and photodiagnosis (Stummer et al., 1998; Tunstall et al., 2002) . Clinically, it was demonstrated that malignant gliomas (Stummer et al., 1998) , colonic and gastrointestinal dysplasia , malignant lesions of the esophagus (Hinnen et al., 1998) , bladder cancer (Kriegmair et al., 1996) , basal and squamous carcinoma (Orenstein et al., 1995 (Orenstein et al., , 1996 Malik et al., 1998) and cutaneous lymphoma (Orenstein et al., 2000) produce excess PpIX following 5-ALA administration. One possible rationale for the specificity of PpIX accumulation through increased PBGD activity in rapidly dividing cancer cells is that their enhanced metabolism demands additional heme, which is mandatory for an increased aerobic ATP supply connected to the energy demands of the tumor. However, it is unclear whether the increase in PBGD activity is dependent upon malignant transformation itself, or upon the increased growth rate of the cells (Schoenfeld et al., 1998) .
The first enzyme of the biosynthetic pathway (ALAsynthase) and the two last enzymes (PBG oxidase and ferrochelatase) are known to be mitochondrial enzymes while all other enzymes are exclusively localized in the cytoplasm (Ponka, 1997) . Recently, we showed that PBGD is imported into the nucleus of glioma C6 cells in addition to the fraction, that remains in the cytoplasm (Greenbaum et al., 2002) . Nuclear import of many proteins was shown to be dependent on a specific import mechanism via RanGTPase and on the cytosolic or nuclear localization of this enzyme (Yoneda, 2000; Quimby and Corbett, 2001 ). RanGTPase localization is dependent upon the nucleotide to which it is bound (Sazer and Dasso, 2000) , with RanGTP and RanGDP comprising the nuclear and cytoplasmic pools of Ran, respectively (Chuanmao et al., 1999) . Two main nuclear factors interact with RanGTPase: the nucleotide exchange factor RCC1 that is located on the chromatin (Nemergut et al., 2001) , and the novel Ran binding protein RanBPM of unknown function (Nishitani et al., 2001 ).
We have shown that the PBGD, including the nuclear fraction, is downregulated during butyrate-induced cell differentiation of glioma (Greenbaum et al., 2002) and melanoma cells (not yet published), which points to a possible nuclear function of PBGD. Butyrate-dependent induction leads to histone hyperacetylation via inhibition of histone deacetylase (ADAC), inhibition of histone phosphorylation, and DNA methylation (Archer and Hodin, 1999) . A second differentiation agent, HMBA, is a potent leukemia differentiation inducer (Marks et al., 1994) , which stimulates both the porphyrin biosynthesis pathway and expression of globin genes (Marks et al., 1987 (Marks et al., , 1994 . Ortel et al. has shown that cellular differentiation increases PpIX synthesis from exogenous ALA in a variety of cancer cell lines (Ortel et al., 1998) .
Since the PBGD nuclear function is unresolved, we used the two-hybrid system to ask which proteins are able to interact with PBGD. Both the two-hybrid system and subsequent immunoprecipitation experiments showed that there is PBGD-RanBPM crosstalk, suggesting a possible involvement of the Ran trafficking system in PBGD cellular localization. Subcellular localization of PBGD was examined during mitosis and PBGD protein and enzymatic levels were monitored during butyrate and HMBA glioma-induced differentiation.
Results
PBGD is known to be a cytoplasmic enzyme of the heme biosynthesis pathway (Ponka, 1997) . Recently, we have shown nuclear concentration of PBGD in C6 glioma cells (Greenbaum et al., 2002) . Figure 1 shows nuclear localization of PBGD in interphase, unsynchronized C6 cells. Chromosomal staining was observed in about 5% of mitotic cells, while in metaphase and anaphase cells chromatids were intensely stained when compared to the interphase chromatin (Figure 1b and c, respectively) . When comparing the total cellular versus nuclear PBGD enzymatic activity, we found that the nuclear fraction constitutes about 30% of total enzyme (Figure 1d ).
In order to identify the proteins interacting with fulllength housekeeping-mouse PBGD, we performed a yeast two-hybrid screen in which 3.5 Â 10 6 independent clones from a 17-day mouse embryo cDNA library were screened. We isolated two clones (pACT2-RanBPM) using a Y190 yeast strain expressing pAS2.1-PBGD fused in frame with a GAL-4-binding domain (constructed in pAS2-1). These clones encoded two overlapping sequences corresponding to RanBPM (Figure 2a ): the first clone contains the amino acids alanine 129 -glycine 317 (the continuous underline); the second clone contains valine 158 -aspargine 328 (the stripped underline), which were fused in frame with the GAL-4-activating domain (constructed in pACT2). The nucleotide sequences were deposited into the NCBI GeneBank database (Accession No. AB0055311). To affirm our finding, we immunoprecipitated endogenous human-RanBPM from HeLa cell lysate with antibody prepared against human RanBPM, and detected PBGD (44 kDa) by Western blotting (Figure 2b lane 3, two upper panels). No precipitation reaction was seen when protein G-sepharose beads without RanBPM antibody and beads preincubated with nonspecific rabbit-IgG antibody were used as negative controls in lanes 1 and 2, respectively. The reciprocal assay supported that finding. When we immunoprecipitated endogenous human PBGD with antibody prepared against human-PBGD, RanBPM (90 kDa) was detected by Western blotting (Figure 2b lane 3, two lower panels) . A/G-agarose beads without PBGD antibody, and PBGD antibodies preincubated with purified PBGD protein, were used for coimmunoprecipitation as negative controls (lanes 1 and 2, respectively). In these lanes, anti-RanBPM antibodies did not recognize RanBPM. Double immunolabeling revealed the same nuclear localization for both endogenous RanBPM (Red) and HA-tagged PBGD (Blue) in HeLa cells (Figure 3 ).
Characteristic differentiation of C6 glioma cells was demonstrated by high levels of glutamine-synthetase after 16 h of stimulation with butyrate and HMBA; levels that further increased over time ( Figure 4 ). These findings, along with cell cycle G1 arrest (data not shown), indicated a transition from premature glioma cells to astrocytes following butyrate and HMBA treatment.
Since PBGD was found to interact with RanBPM, we thought it necessary to examine the correlation between PBGD, Ran, and RCC1 levels during differentiation with butyrate and HMBA. Figure 5 shows that PBGD amount in the nuclear fraction was low in comparison to the cytoplasmic fraction. Both nuclear and cytoplasmic levels of PBGD significantly declined following butyrate treatment. Measurements were made at 16, 20, 24, 48 and 72 h. A concomitant reduction was observed in the levels of Ran and its nucleotide exchange factor RCC1 following butyrate induction of differentiation. Actin levels were used as an internal protein control ( Figure 5 ).
C6 glioma induced to differentiate by treatment with HMBA increased cytoplasmic PBGD levels after 24 h, whereas no change in PBGD levels was observed in the nuclear fraction ( Figure 6 ). Similarly, neither Ran nor RCC1 levels changed during induction with HMBA. As cited above, actin levels were used as an internal protein control ( Figure 6 ).
Although PBGD levels were influenced by butyrate and HMBA-induced differentiation, RT-PCR analysis showed no change in the PBGD mRNA levels following butyrate and HMBA induction ( Figure 7) .
The relationship between PBGD enzymatic activity and differentiation in glioma cells showed a timedependent decrease in PBGD activity following butyrate treatment, whereas no significant changes were observed following HMBA treatment ( Figure 8a ). After 16 h of induction with butyrate, PBGD activity was reduced from 74 to 55 pmol uroporphyrin mg À1 protein per 1 h, and remained constant over the next 4 h. A moderate reduction was seen between 20 and 24 h postinduction, while a fivefold reduction was observed between 24 and 48 h and a minimal PBGD activity was measured after Figure 2 Protein screening for interaction with full-length PBGD using two-hybrid system. (a) Two clones were found to interact with PBGD, corresponding to RanBPM: the first contains the amino-acid sequence alanine 129 -glycine 317 (the continuous underline) and the second contains the amino-acid sequence valine 158 -aspargine 328 (the stripped underline). (b) Endogenous PBGD from HeLa cells lysate was co-precipitated with endogenous RanBPM using anti-RanBPM antibody (two upper panels). The resulting precipitates were analysed by immunoblotting using antibodies reacting with PBGD (upper panel, lane 3) or with RanBPM (lower panel, lane 3). G-sepharose beads without RanBPM antibody or with nonspecific rabbit-IgG antibody were used for negative controls (lanes 1 and 2, respectively). For the reciprocal assay, endogenous RanBPM was co-precipitated with endogenous PBGD using anti-PBGD antibodies (two lower panels). The resulting precipitates were analysed by immunoblotting using antibodies reacting with RanBPM (upper panel, lane 3) or with PBGD (lower panel, lane 3). A/G-agarose beads without PBGD antibody, and PBGD antibodies preincubated with purified PBGD protein, were used as negative controls (lanes 1 and 2, respectively) Porphobilinogen deaminase; RanBPM and differentiation L Greenbaum et al 72 h. Only a minor reduction in PBGD activity was recorded during induction with HMBA at the 48-72 h interval (Figure 8a) . A positive correlation was found between PBGD activity during glioma differentiation and PpIX production for both butyrate and HMBA (Figure 8b) . A 30% reduction in PpIX synthesis was measured at 16 and 20 h of butyrate treatment. An additional 45% reduction of PpIX was seen during the 24-72 h interval of butyrate stimulation and only 10% reduction was observed after 72 h of HMBA.
Discussion
PBGD is a rate-limiting enzyme in the PpIX synthesis pathway and thus a key enzyme controlling ALA-PDT (Gibson et al., 1998) . The activity of PBGD is strongly correlated with an increased growth rate in both nonmalignant and malignant cell lines (Schoenfeld et al., 1998) . One possible rationale for the specificity of PpIX accumulation in rapidly dividing cells is that their enhanced metabolism demands additional heme, which is needed for increased aerobic ATP supply connected to the energy demands of the tumor. Recently, we showed that PBGD is partially localized to the nucleus in addition to that found in the cytosol, where it is responsible for PpIX synthesis (Greenbaum et al., 2002) . Here, we show that PBGD appears to be a component of the condensed chromatin of metaphase and anaphase cells, whereas PBGD appears evenly distributed in the interphase nucleus in addition to its presence in the cytoplasm. This phenomenon was detected in the mitotic cells consisting 5% of the unsynchronized cells in the culture. The two-hybrid screening system, which uses housekeeping PBGD as bait, revealed an interaction with a nuclear protein identified as the Ran-binding protein, RanBPM. RanBPM is a 90 kDa protein localized both in the nucleus and in the cytoplasmic region surrounding the centrosome, but not within the centrosome itself (Nishitani et al., 2001) . RanBPM is well conserved in the animal kingdom and is suggested to be part of a large protein complex of more than 670 kDa, containing at least five proteins. One of those proteins has a molecular weight of 45 kDa (Nishitani et al., 2001) , similar to the size of PBGD.
Recently, several more cell-cycle-related proteins were found to interact with RanBPM, such as the ubiquitinspecific protease USP11 (Ideguchi et al., 2002) and the receptor protein tyrosine kinase of the hepatocyte growth factor (Wang et al., 2002) . Although RanBPM is a Ran-binding protein, it is unclear whether RanBPM participates in protein shuttling between the nucleus and cytoplasm via a RanGTPase mechanism. Nuclear import and export mechanisms require specific signals: nuclear localization and nuclear export signals, respectively. The transport pathways are highly divergent, and are largely mediated by the importin b-like transport receptor family of molecules (Yoneda, 2000) . These receptor molecules bind to, and carry their cargoes directly or via specific adaptors. The small RanGTPase ensures directional nucleo-cytoplasmic protein trafficking, dependent on the GTP/GDP state (Izaurralde et al., 1997) . Ran has a low intrinsic activity of GDP/GTP hydrolysis and therefore, the RanGTPase cycle is regulated by various interacting proteins (Kuersten et al., 2001 ). The guanine nucleotide exchange factor of Ran, RCC1, which is anchored within the chromatin (Nemergut et al., 2001) accelerates the dissociation of guanine nucleotide from Ran resulting in the conversion of RanGDP to RanGTP, only in the nucleus (Kuersten et al., 2001) . The interaction between PBGD and a Ranbinding protein may be related to the nuclear transport mechanism of PBGD.
Since PBGD was found within the condensed chromatin during mitosis and is a key enzyme in the heme synthesis pathway, we believe that PBGD plays a role in cell-cycle regulation. Figures 5 and 6 reveal a correlation between the levels of nuclear PBGD, Ran and RCC1 as a direct effect of glioma cell differentiation induced by butyrate and HMBA. The C6 glioma model system has oligodendrocytic, astrocytic, and neuronal properties (Parker et al., 1980; Segovia et al., 1994) and is widely used to study differentiation processes. Astrocyte-like differentiation of the C6 cells is characterized by upregulation of glutamine synthetase (GS) (Dot et al., 2002) followed by morphological changes. We show that both butyrate and HMBA induced glioma C6 differentiation to astrocyte-like cells, each by distinct mechanisms. Butyrate is an inhibitor of histone deacetylase (HDAC) (Archer and Hodin, 1999) and promotes histone hyperacetylation of DNA. Since histone acetylation and deacetylation contribute to transcriptional activation and repression, they are likely to be involved in regulating genes required for differentiation (eg the p21 gene) (Cheung et al., 2000) . Recent studies implicate hyperacetylation and deacetylation as playing an important role in oncogenesis (Archer and Hodin, 1999) . Unlike butyrate, HMBA is a potent inducer of differentiation belonging to the group of hybrid polar compounds (Rifkind et al., 1996) , so that its essential feature is a combination of hydrophobicity and a high dipole moment (Breslow et al., 1991) , and thus its cellular target is the plasma membrane (Arcangeli et al., 1987) . HMBA acts by modulating the surface potential of the cell (Arcangeli et al., 1993) , and some other findings suggest that a PKC-modulated signaling pathway may be involved in HMBA-induced murine erythroleukemia cell differentiation (Marks et al., 1994) . The differences between butyrate and HMBA are remarkable in their influence on PBGD activity, PpIX synthesis and on its nuclear localization. Butyrate induces moderate 'relaxation' of chromatin (Annunziato et al., 1988) that probably affects PBGD anchoring within nuclear components. The RT-PCR result suggests a post-transcriptional regulation of total cellular PBGD. In addition, the appearance of PBGD in the nucleus is closely related to the cell differentiation stage. This specific relationship resembles the regulation of the transferrin receptor (another component in heme synthesis), which is regulated on a post-transcriptional level by iron responsive elements (IREs) (McLintock and Fitzsimons, 2002) .
The successful oncologic use of ALA-photodynamic therapy is highly dependent on the level of PpIX accumulation in the treated tumors, in which PBGD functions are key players, correlated with the differentiation stage of the tumor. PBGD binding to the chromatin and PBGD interaction with RanBPM implicate a novel regulatory function for PBGD, possibly involved in cellular events that regulate changes from proliferation to differentiation. This function and its relationship to cell energy demands during tumorigenesis should be defined.
Materials and methods

Cell culture
Rat C6 glioma and human HeLa cells were grown on tissue culture plates (Corning, Staffordshire, UK) in a DMEM medium (Biological Industries, Kibbutz Beit-Haemek, Israel), supplemented with 10% fetal calf serum and antibiotics, and incubated at 371C in a humidified atmosphere with 8% CO 2 . The cells were recultured twice a week, using trypsin-EDTA for detachment.
Nucleus/cytoplasm fractionation C6 cells were harvested and resuspended in Tris-HCl buffer supplemented with EDTA, EGTA, leupeptine (42 mm), aprotinine (1.5 mm), PMSF (100 mm) and DTT (1 mm) (Sigma, St Louis, MO, USA). For nucleus-cytoplasm fractionation, cells were homogenized on ice using a manual glass homogenizer (A. Shitzer, Haifa, Israel) followed by centrifugation at 2500 r.p.m. for 10 min (twice). The pellet containing the nuclear fraction was resuspended in the above buffer containing 0.4 m NaCl on ice for 1 h. The nuclear and cytoplasmic samples were centrifuged at 14 000 r.p.m. at 41C for 1 h and the supernatant was collected for further work.
Western blotting
Proteins were quantified using the Bradford assay (Bio-Rad, Hercules, CA, USA) and resolved on a 12% polyacrylamide gel. Thereafter, proteins were transferred onto nitrocellulose membranes using a semi-dry transfer apparatus (Bio-Rad, Hercules, CA, USA). After blocking of the membranes with 5% skimmed milk and 0.06% Tween-20 in PBS, membranes were incubated with primary rabbit anti-human PBGD antibody (a generous gift from HemeBiotech, Stockholm, Sweden), anti-human Ran and rat glutamine-synthetase monoclonal antibodies (BD Transduction Laboratories, Franklin Lakes, NJ, USA), goat anti-human RCC1 antibody (Santa Cruz, Santa Cruz, CA, USA), anti-actin monoclonal antibody (Sigma, St Louis, MO, USA), rabbit anti-human RanBPM antibody (a generous gift from Takeharu Nishimoto, Kyushu University, Japan) and HRP anti-rabbit/mouse/ goat secondary antibody (Jackson Immuno-Research, West Grove, PA, USA) in the same solution. Immunoreactive proteins were visualized with an enhanced chemiluminescence detection kit (Amersham Pharmacia, Piscataway, NJ, USA) used as recommended by the manufacturer.
RT-PCR of PBGD
Total RNA was extracted from butyrate/HMBA-treated C6-glioma cells using the Rneasy Mini kit (Qiagen GmbH, Hilden, Germany). RT-PCR was carried out using RT-PCR beads (Amersham Pharmacia, Piscataway, NJ, USA) as recommended by the manufacturer, using 5 0 -ATGAGGGTGATTC-GAGTGGG-3 0 forward primer and 5 0 -TTAGCGCACAT-CATTAAGCTG-3 0 reverse primer.
Double Immunolabeling of PBGD and RanBPM
HA-PBGD was constructed by a PCR reaction using forward primer 5 0 -CGGGATCCCGGCCGCCACCATGGCTTACC-CATACGATGTTCCAGATTACGCTATGTCTGGTAAC-GGCAATGCGGC-3 0 and reverse primer 5 0 -CGGGAT-CCCGTTAATGGGCATCGTTAAGCTGCCG-3 0 . The amplified construct was inserted into the pEGFP-C1 vector (Clontech, Palo Alto, CA, USA) following BamHI digestion in both sides, and after the GFP-encoded region was removed by digestion of the vector with Eco47III and SmaI. HeLa cells were transfected with HA-PBGD plasmid using lipofectamine (GIBCO-BRL, Gaithersburg, MD, USA). After 24 h, cells were fixed using 4% paraformaldehyde and subsequently treated with 0.5% Triton X-100 for 35 min. Blocking was carried out with 6% skimmed milk, 1% BSA, and 0.2% Tween-20 in 100% fetal calf serum. Cells were then exposed to rabbit anti-human RanBPM antibody (a generous gift from Takeharu Nishimoto, Kyushu University, Japan) and mouse anti-HA-tag antibody (fused to human-PBGD) (Berkeley Antibody Company, Richmond, CA, USA) overnight at 41C in PBS solution containing 1% BSA and 0.2% Tween-20, and then reacted with rhodamine-conjugated anti-rabbit antibodies (Jackson Immuno-Research, West Grove, PA, USA) and Alexa Fluor s 350 goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA) in distilled water for 1 h. Cells were dehydrated by ethanol and then covered with Entellan mounting media (Merck, Darmstadt, Germany). The cells were visualized with fluorescence microscopy (Olympus AX70).
Enzymatic activity assay for PBGD PBGD was assayed by determining the absorbance of uroporphyrin formed by light-induced oxidation of uroporphyrinogen, which is the immediate product of the enzymatic deamination. 10 6 C6 cells were detached from plates at certain times of butyrate and HMBA induction, and resuspended in PBS without Ca 2 þ /Mg 2 þ . After centrifugation, the pellet was resuspended in 250 ml 50 mm Tris buffer (pH 8.2) and 0.2% Triton. The lysate was homogenized on ice and 100 ml was taken out for incubation with a final concentration of 85 mm PBG (Porphyrin Products, Logan, UT, USA) in 500 ml of 50 mm Tris buffer (pH 8.2) contains 0.2% Triton, for 1 h at 371C with shaking. The reaction was stopped by addition of 10% TCA under exposure to ambient room light at room temperature for 10 min. After 10 min centrifugation (3300 r.p.m.), the supernatant was collected to the spectrofluorometer (ex. 409 nm, em. 595 nm) (Spectronic Instruments, Leeds, UK). PBGD specific activity is calculated as pmol uroporphyrin formed/mg protein/1 h units.
PpIX accumulation assay
C6 cells were treated with butyrate and HMBA for certain periods of time. At 4 hours before each point of time, 0.6 mm 5-ALA (Clontech, Palo Alto, CA, USA) in serum-free medium was added to cells and the cells were detached from the plates and centrifuged at 1100 r.p.m., followed by resuspension in glacial acetic acid. The cells were sonicated on ice and ethyl acetate was added (v/v 1 : 3). The samples were centrifuged at 3300 r.p.m. for 15 min, and the supernatant was transferred to 1 m HCl. After 5 min of shaking, the lower phase was collected and read using a spectrofluorometer (ex. 405, em. 620). The results were calculated as a mean of five experiments and expressed as %PpIX formed per mg protein during 4 h incubation with 5-ALA.
Two-hybrid screen and coimmunoprecipitation
The Matchmaker two-hybrid system 3 (Clontech, Palo Alto, CA, USA) was used according to the manufacturer's protocol. Using polymerase chain reaction-based strategies, we subcloned the sequence encoding the housekeeping PBGD into the pAS2-1 vector (at SmaI and SalI sites) as bait, to generate a fusion protein with a GAL4 DNA-binding domain (pAS-PBGD). The forward primer used for this purpose was 5 0 -TCCCCCGGGGATGTCCGGTAACGGCGGC-3 0 , and the reverse primer: 5 0 -ACGCGTCGACTTAGCGCACATCAT-TAAGCTG-3 0 . AH-109 host strain (MATa, 112, gal4D , gal80D, LYS2::GAL1 UAS -GAL1 TATA -his3, GAL2 UAS -GAL2 TATA -UDE2, URA3::ME-L1 UAS -MEL1 TATA -lacZ) was transformed with the bait plasmid by the lithium acetate method as described in the manufacturer's protocol and mated the Y187 strain (MATa, 112, gal4D , met À , gal80D: URA3::GAL1 UAS , ÀGAL1 TATA , ÀlacZ) containing a 17-day mouse embryo cDNA library. We grew 7 Â 10 6 transformants on selective high stringency minimal plates (-Ade/-His/-Leu/-Trp/X-a-gal) containing 35 mm 3-aminotriazole for 14 days at 301C. The positive clones were assayed by b-galactosidase according to the manufacturer's protocol to confirm the specific association. Plasmids from the positive clones were column-purified and sequenced using primers complementary to pACT2 as recommended by the manufacturer (Weizmann Institute Biological Services, Rehovot, Israel).
For verifying the interaction between PBGD and RanBPM, crude lysate from HeLa cells was extracted using a buffer containing 20 mm Tris-HCl pH 7.4, 150 mm NaCl, 1 mm EDTA, 0.1% NP-40, 2 mm sodium orthovanadate, 0.5% deoxycholate at 41C for 30 min. Supernatant collected after 14 000 r.p.m. centrifugation was incubated with BSA precoated protein A/G PLUS-Agarose beads (Santa Cruz, Santa Cruz, CA, USA) for PBGD precipitation with anti-PBGD antibody, and protein G Sepharoset 4 fast flow beads (Amersham Pharmacia, Piscataway, NJ, USA) for RanBPM precipitation with anti-PBGD antibody for 15 min at 41C. This step is crucial for nonspecific protein absorption to the beads. After a 5 min centrifugation at 14 000 r.p.m., the supernatant was incubated with the BSA precoated beads binding to anti-PBGD or anti-RanBPM antibody at 41C overnight. The PBGD/RanBPM was precipitated by centrifugation of the beads and washed twice with the above buffer, and one more time with PBS without Ca 2 þ /Mg 2 þ . The pellet was suspended in sample buffer containing SDS and boiled for 5 min. The samples were detected on PAGE-SDS as described before, and the nitrocellulose membrane was reacted against antiRanBPM/PBGD antibody. A/G-agarose beads without PBGD antibody, and PBGD antibodies preincubated with purified PBGD protein (a generous gift from HemeBiotech, Stockholm, Sweden) were used as negative controls for the precipitation with anti-PBGD antibody. Protein G sepharoset 4 fast flow beads without PBGD antibody, and nonspecific rabbit-IgG antibody (Santa Cruz, Santa Cruz, CA, USA) were used as negative controls for the precipitation with antiRanBPM antibody.
